Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow, Harald Hampel, Michael W. Weiner, et al.
Nature Reviews Neurology (2010) Vol. 6, Iss. 3, pp. 131-144
Closed Access | Times Cited: 1766

Showing 1-25 of 1766 citing articles:

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack, David A. Bennett, Kaj Blennow, et al.
Alzheimer s & Dementia (2018) Vol. 14, Iss. 4, pp. 535-562
Open Access | Times Cited: 7834
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois, Howard Feldman, Claudia Jacova, et al.
The Lancet Neurology (2014) Vol. 13, Iss. 6, pp. 614-629
Open Access | Times Cited: 3006
Alzheimer's disease
Philip Scheltens, Kaj Blennow, Monique M.B. Breteler, et al.
The Lancet (2016) Vol. 388, Iss. 10043, pp. 505-517
Closed Access | Times Cited: 2740
Revising the definition of Alzheimer's disease: a new lexicon
Bruno Dubois, Howard Feldman, Claudia Jacova, et al.
The Lancet Neurology (2010) Vol. 9, Iss. 11, pp. 1118-1127
Closed Access | Times Cited: 1828
2018 Alzheimer's disease facts and figures

Alzheimer s & Dementia (2018) Vol. 14, Iss. 3, pp. 367-429
Closed Access | Times Cited: 1803
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson, Ronald Lautner, Ulf Andréasson, et al.
The Lancet Neurology (2016) Vol. 15, Iss. 7, pp. 673-684
Open Access | Times Cited: 1778
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Bruno Dubois, Harald Hampel, Howard Feldman, et al.
Alzheimer s & Dementia (2016) Vol. 12, Iss. 3, pp. 292-323
Open Access | Times Cited: 1646
Alzheimer's disease
Colin L. Masters, Randall J. Bateman, Kaj Blennow, et al.
Nature Reviews Disease Primers (2015) Vol. 1, Iss. 1
Closed Access | Times Cited: 1432
Clearance systems in the brain—implications for Alzheimer disease
Jenna M. Tarasoff-Conway, Roxana O. Carare, Ricardo S. Osorio, et al.
Nature Reviews Neurology (2015) Vol. 11, Iss. 8, pp. 457-470
Open Access | Times Cited: 1385
The Amyloid-β Pathway in Alzheimer’s Disease
Harald Hampel, John Hardy, Kaj Blennow, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 10, pp. 5481-5503
Open Access | Times Cited: 1041
Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis
Yasser Iturria‐Medina, Roberto C. Sotero, P.-J. Toussaint, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 995
Plasma phospholipids identify antecedent memory impairment in older adults
Mark Mapstone, Amrita K. Cheema, Massimo S. Fiandaca, et al.
Nature Medicine (2014) Vol. 20, Iss. 4, pp. 415-418
Open Access | Times Cited: 964
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Shorena Janelidze, Niklas Mattsson, Sebastian Palmqvist, et al.
Nature Medicine (2020) Vol. 26, Iss. 3, pp. 379-386
Open Access | Times Cited: 935
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Michael Erkkinen, Mee-Ohk Kim, Michael D. Geschwind
Cold Spring Harbor Perspectives in Biology (2017) Vol. 10, Iss. 4, pp. a033118-a033118
Open Access | Times Cited: 932
Huntington disease: natural history, biomarkers and prospects for therapeutics
Christopher A. Ross, Elizabeth Aylward, Edward J. Wild, et al.
Nature Reviews Neurology (2014) Vol. 10, Iss. 4, pp. 204-216
Closed Access | Times Cited: 903
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Ian W. Hamley
Chemical Reviews (2012) Vol. 112, Iss. 10, pp. 5147-5192
Open Access | Times Cited: 840
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson, Ulf Andréasson, Henrik Zetterberg, et al.
JAMA Neurology (2017) Vol. 74, Iss. 5, pp. 557-557
Open Access | Times Cited: 823
Biomarkers for Alzheimer's disease: current status and prospects for the future
Kaj Blennow, Henrik Zetterberg
Journal of Internal Medicine (2018) Vol. 284, Iss. 6, pp. 643-663
Open Access | Times Cited: 779
What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus
Anders M. Fjell, Linda K. McEvoy, Dominic Holland, et al.
Progress in Neurobiology (2014) Vol. 117, pp. 20-40
Open Access | Times Cited: 736
The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives
Russell H. Swerdlow, Jeffrey M. Burns, Shaharyar M. Khan
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2013) Vol. 1842, Iss. 8, pp. 1219-1231
Open Access | Times Cited: 696
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler, James G. Bollinger, Vitaliy Ovod, et al.
Neurology (2019) Vol. 93, Iss. 17
Open Access | Times Cited: 674
Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
Peder Buchhave
Archives of General Psychiatry (2012) Vol. 69, Iss. 1, pp. 98-98
Closed Access | Times Cited: 624
CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Oskar Hansson, John Seibyl, Erik Stomrud, et al.
Alzheimer s & Dementia (2018) Vol. 14, Iss. 11, pp. 1470-1481
Open Access | Times Cited: 619
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer, Joseph J. Locascio, Walter Schulz‐Schaeffer, et al.
The Lancet Neurology (2011) Vol. 10, Iss. 3, pp. 230-240
Closed Access | Times Cited: 597
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Harald Hampel, Sid E. O’Bryant, José Luís Molinuevo, et al.
Nature Reviews Neurology (2018) Vol. 14, Iss. 11, pp. 639-652
Open Access | Times Cited: 555
Page 1 - Next Page

Scroll to top